AI assistant
Dr. Lal Pathlabs Limited — Earnings Release 2025
Jan 30, 2025
61783_rns_2025-01-30_3a162915-0e15-42a5-9ac3-16144dd947c3.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [598 x 65] intentionally omitted <==
January 30, 2025
National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524
Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2024
Dear Sir/ Madam,
Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2024.
We request you to please take the same on record.
Thanking You,
Yours Faithfully,
For Dr. Lal PathLabs Limited
VINAY Digitally signed by VINAY GUJRAL GUJRAL Date: 2025.01.30 14:01:28 +05'30'
Vinay Gujral Company Secretary & Compliance Officer
Encl.: As above
Classification: Internal
January 30, 2025
For Immediate Release
==> picture [159 x 37] intentionally omitted <==
Dr Lal PathLabs Limited records revenue of Rs 597 Cr in Q3 FY 2024-25
New Delhi, India, January 30, 2025 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2024.
Consolidated Performance Highlights: Q3 FY25 vs Q3 FY24
-
Revenue increased by 10.7% in Q3 FY25
-
EBITDA increased by 9.6% with a margin of 25.8%
-
PAT increased by 19.3% with a margin for of 16.4%
-
Third Interim Dividend of Rs. 6 per share for FY25
Financial Overview (Consolidated) in Rs Cr
| Particulars | Q3 | Q3 | Q3 | YTD | YTD | YTD |
|---|---|---|---|---|---|---|
| FY25 | FY24 | Gr % | FY25 | FY24 | Gr % | |
| Revenue | 597 | 539 | 10.7% | 1859 | 1681 | 10.6% |
| Operating Expenditure | 443 | 398 | 11.1% | 1332 | 1217 | 9.5% |
| EBITDA | 154 | 141 | 9.6% | 527 | 465 | 13.3% |
| Margins Other Income Depreciation Cost |
25.8% 25 36 |
26.1% 18 36 |
28.3% 68 106 |
27.6% 51 107 |
||
| EBIT | 144 | 123 | 16.8% | 489 | 408 | 19.6% |
| Margins Finance Cost |
24.1% 5 |
22.8% 7 |
26.3% 17 |
24.3% 23 |
||
| PBT | 138 | 116 | 19.4% | 471 | 386 | 22.2% |
| Margins | 23.2% | 21.5% | 25.4% | 22.9% | ||
| PAT | 98 | 82 | 19.3% | 337 | 277 | 21.8% |
| Margins | 16.4% | 15.3% | 18.1% | 16.4% | ||
| EPS | 11.6 | 9.8 | 18.7% | 39.9 | 32.9 | 21.4% |
About Dr Lal PathLabs Limited
Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Dr Lal Pathlabs Limited
1
12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com
==> picture [159 x 37] intentionally omitted <==
As on March 31, 2024 the company has 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.
Contact Details
Ved Goel Group Chief Financial Officer Dr Lal PathLabs Limited
+91 124 3016500 [email protected]
Kritika Khatwani Adfactors PR
+91 8604801332 [email protected]
For further information on Dr Lal PathLabs see www.lalpathlabs.com
Safe Harbour
This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.
Dr Lal Pathlabs Limited
2
12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com